VANQUISH-1
39 evidence topics · 16 sources
Objective
Study objective in the ClinicalTrials.gov record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-06-23” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-07-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-08-05” (opens the source at this quote in a new tab)
“Last Update Posted 2025-11-24” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Number of randomizing sites in the baseline poster
Initiation and completion of enrollment
Expected completion and timing of data
Study design
Design, duration, randomization ratio, and stratification
Official title in the ClinicalTrials.gov record
Allocation of fewer participants to the lowest dose
Diversity plan
Extension study after the 78-week treatment period
Eligibility criteria
Key inclusion and exclusion criteria in the design poster
“Adults ≥18 years of age” (opens the source at this quote in a new tab)
“BMI ≥30 kg/m2 or” (opens the source at this quote in a new tab)
“History of diabetes” (opens the source at this quote in a new tab)
“Prior or planned bariatric surgery” (opens the source at this quote in a new tab)
“History of acute or chronic pancreatitis” (opens the source at this quote in a new tab)
“Impaired renal function” (opens the source at this quote in a new tab)
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |
Subcutaneous formulation: dose arms and lifestyle counseling
Subcutaneous formulation: dose titration from 1.25 mg
Subcutaneous formulation: transition from vial and syringe to autoinjector
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint
Secondary endpoint: categorical weight reduction
Additional outcomes: function, cardiometabolic health, mental health, and work productivity
Regulatory basis for the primary endpoint and for responder analyses
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Enrollment reported after completion
Description of analysis sets
Population analyzed for baseline characteristics
Efficacy and safety analysis sets
No evidence found.
Results
Participant disposition
Blinded discontinuation rate across the VANQUISH program
Baseline characteristics
Demographics and body size compared with NHANES
| Characteristic | VANQUISH-1 (N=4660) | NHANES |
|---|---|---|
| Age, mean (SD), years | “50.4 (13.81)” | “47.6 (13.97)” |
| Age 65 years or older | “17%” | “19%” |
| Sex, female to male | “65%:35%” | “51%:49%” |
| Waist circumference, mean (SD), cm | “116.2 (16.13)” | “109.2 (11.35)” |
| BMI, mean (SD), kg/m2 | “38.3 (7.31)” | “33.7 (5.10)” |
| BMI 27 to less than 30 kg/m2 | “5%” | “33%” |
| BMI 30 to less than 35 kg/m2 | “33%” | “36%” |
| BMI 35 to less than 40 kg/m2 | “28%” | “16%” |
| BMI 40 kg/m2 or higher | “33%” | “15%” |
Baseline comorbidities
Baseline laboratory values
| Measurement, mean (SD) | VANQUISH-1 (N=4660) |
|---|---|
| HbA1c, % | “5.5 (0.40)” |
| Glucose, mg/dL | “97.2 (11.18)” |
| Insulin, µIU/mL | “16.4 (15.66)” |
| Total cholesterol, mg/dL | “192.6 (39.69)” |
| Triglyceride, mg/dL | “126.8 (61.85)” |
| hsCRP, mg/L | “6.0 (8.82)” |
Representativeness stated by the authors
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations evident from the available VANQUISH-1 documents
VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.
Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.
The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.